United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

United Therapeutics is also proud to sponsor ... beginning to reveal clues that could help to efficiently detect pulmonary hypertension associated with interstitial lung disease,” said Andrew ...

Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the ...

Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of ...

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

United Therapeutics Corporation ... injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of ...

DelveInsight's Pulmonary Arterial Hypertension Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 9, 2025 ...

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension ... became widely used in the United States but were withdrawn ...

At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the SILVER SPRING, Md. & RESEARCH TRIANGLE ...